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Abstract
Background: Dornase alpha improves sputum clearance and pulmonary function in patients with moderate bronchiectasis and
cystic fibrosis (CF). Several studies have demonstrated variable adherence to treatment regimens in patients with CF. We aimed
to compare self-reported adherence with computer based dispensing records of dornase alpha. Method: Direct interview of
adherence to dornase alpha was compared with pharmacy-dispensing records during a 12-month period. The reasons for dornase
alpha usage, and change in lung function in three groups of patients were compared (group 1 (ns42): positive trial, continuing
therapy; group 2 (ns13): positive trial, ceased therapy; group 3 (ns22): negative trial). Ninety patients with CF were surveyed.
Patients who had ceased dornase alpha provided reasons for drug cessation. Lung function and anthropometric data were collected
prior to dornase alpha treatment and at 3 years. Health care professionals rated adherence to therapy. Results: Of the 42 patients
on dornase alpha, the average utilisation was 197 days (54%). From dispensing records, 24% of patients were classified as good
adherence, 46% as moderate adherence and 30% as poor adherence. Eighty-two percent claimed to use dornase alpha therapy
more than 20 daysymonth, whereas dispensing records showed that only 24% of collected sufficient drug supplies. Health
professionals’ assessment of adherence of therapy was often incorrect and an overestimation was more common than
underestimation. The change in FEV 3 years after trial was not significantly different between groups. There was a negative1
correlation between initial response to dornase alpha and baseline FEV (rsy0.44, Ps0.001), however, initial response was not1
related to the change in FEV over 3 years (rs0.20, Ps0.16). Conclusion: There is variability in adherence to dornase alpha in1
adults with CF and patient self-reporting is likely to over-estimate drug collection from the pharmacy. Further study of the long-
term effects of dornase alpha is required. To date, proven interventions to enhance adherence are limited and require investigation
in CF.
 2002 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Chronic infection of the airways is responsible for
more than 90% of mortality and the majority of morbid-
ity in cystic fibrosis (CF). The basic defect of impaired
epithelial chloride transport, chronic bacterial infection,
and a vigorous host inflammatory response leads to
excessive levels of deoxyribonucleacic acid (DNA) in
airway lining fluid which causes increased viscosity of
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sputum w1x. Recombinant human deoxyribonuclease
(dornase alpha, Pulmozyme ) cleaves DNA in vitro and
when nebulised, reduces sputum viscosity in patients
with CF w2x. Randomised control trials that preceded
the introduction of dornase alpha in the clinical setting
demonstrated short term improvements in pulmonary
function and possibly decreased episodes of pulmonary
exacerbation in patients with moderate lung disease w3–
6x.
Longer-term studies have been observational and
uncontrolled, and have suggested plateauing of improve-
ment in spirometry over periods of up to 2 years w7,8x.
Response to dornase alpha was variable with almost
50% of patients having an improvement in FEV of )1
10% w8x. Milla retrospectively studied pulmonary func-
tion and admissions to hospital in 190 patients with CF,
for 2 years preceding and 2 years following the prescrip-
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tion of dornase alpha (60% had an FEV )80% pre-1
dicted). Overall the group did not have a decreased rate
of decline in lung function and nutritional parameters
following the introduction of dornase alpha and no
change in hospital admission rates occurred. The author
acknowledged that the lack of control over adherence
may have been a confounding factor w9x.
Dornase alpha is an expensive treatment and criteria
for its prescription vary within and between health
systems. In 1996 the Federal Government of Australia
provided special funding, through the Highly Specialised
Drugs Program (Section 100), for dornase alpha pre-
scription for patients with CF. A 10% improvement in
the FEV was required, following a 1-month administra-1
tion of dornase alpha (2.5 mg daily). A therapeutic trial
was indicated in patients with CF who were clinically
stable, with evidence of chronic suppurative lung disease
and had a forced vital capacity of greater than 40%
predicted. Little information is currently available
regarding long-term adherence of dornase alpha when
prescribed in routine clinical practice, however, it is
well known that adherence is sub-optimal for many
aspects of treatment in many patients with CF w10,11x.
This study aimed to assess utilisation and adherence
to dornase alpha in an adult CF clinic. We sought to
determine which patients attending the clinic had pre-
viously had a dornase alpha trial. Of those patients who
had an initial positive trial, we determined which of
those patients who continued dornase alpha more than
3 years after the initial dornase alpha trial. We compared
self-recorded adherence with pharmacy-dispensing
records for dornase alpha. We also assessed the relation-
ship between initial dornase alpha response and its
ongoing usage and changes in lung function during a 3-
year period.
2. Methods
A retrospective study was undertaken between Janu-
ary and April 2000 to determine which patients in the
clinic were taking dornase alpha. The CF pharmacist
conducted a personal interview with 90 patients who
regularly attended the Adult CF Unit (total clinic pop-
ulation 115 patients).
2.1. Patient interview
Patients were asked if they had previously had a
dornase alpha therapeutic trial. If patients had previously
had a dornase alpha trial, patients were asked if they
continued therapy. Of patients who continued therapy
(group 1), patients were asked to approximate the
number of days in an average 30-day month that they
took dornase alpha and were also asked to rate its
effectiveness on a visual analogue (0–10) scale (0—
dornase alpha made no difference at all to sputum
thickness to 10—dornase alpha was highly effective,
leading to thinner sputum). Of patients who had a
previous positive dornase alpha trial who had discontin-
ued therapy (group 2), patients were asked why they
had discontinued therapy. Of patients who had a negative
dornase alpha trial (group 3), patients were asked of
their perceived benefit from dornase alpha during the
trial period, and if they were interested in having another
dornase alpha trial.
2.2. Comparison of self-reported adherence with phar-
macy-dispensing records
Pharmacy-dispensing records for a year (Jan 1999–
Jan 2000) were accessed to determine dates of dispens-
ing of dornase alpha (dispensed as boxes of 30 nebules).
In Australia, dornase alpha is only available through
Government hospital pharmacies. Where a patient
reported obtaining supplies from a hospital other than
at The Prince Charles Hospital, these dispensing records
were also obtained. Patients were classified as good
adherence if 9–12 months’ supply was collected, mod-
erate adherence if 5–8 months of drug were collected,
and poor adherence if 1–4 months’ supply was collect-
ed. The two adult CF physicians and the CF nurse co-
ordinator were also asked to rate patients as good,
moderate or poor adherence, according to the above
criteria, without the knowledge of the dispensing
records. Initial FEV response to the dornase alpha (1-1
month trial period) and change in spirometry over 3
years were compared between patients in three groups.
2.3. Statistical analysis
Mean values with 95% confidence intervals are pre-
sented. Group differences were compared by analysis of
variance (ANOVA) and F values presented. Where
multiple comparisons were required between groups,
bonferroni correction was applied. Relationships
between variables were assessed by the Pearson corre-
lation test to assess the determinants of acute and long-
term changes in spirometry in patients receiving dornase
alpha. A value of P-0.05 was considered as statistically
significant.
3. Results
Ninety patients completed the personal interview with
the CF pharmacist and of these 77 had a therapeutic
trial (Table 1). Forty-two patients (54%) had an initial
positive trial ()10% improvement in FEV ) to dornase1
alpha and continued therapy. A further 13 patients (17%)
had an initial positive dornase alpha, but had subse-
quently ceased therapy, and 22 patients (29%) did not
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Table 1
Pulmonary function and anthropometric data
Group 1 (ns42) Group 2 (ns13) Group 3 (ns22) F valuea Whole clinic
Age (years) 20.7 (4.7) 26.1 (6.9)* 21.6 (6.6) 4.3 26.7 (7.5)
FEV (% predicted)1 53.3 (15.5) 54.1 (20.4) 66.5 (20.2)* 3.7 57.5 (23.0)
FVC (% predicted) 66.0 (15.8) 65.3 (13.6) 79.3 (20.1)* 4.3 72.9 (18.9)
Weight (kg) 59.6 (11.9) 61.3 (12.6) 58.1 (9.3) 0.3 61.5 (11.4)
BMI (kgym )2 21.1 (2.8) 21.0 (3.1) 20.8 (2.8) 0.1 21.3 (2.8)
Group 1—patients who had a positive dornase alpha trial and continued therapy; Group 2—patients who had a positive dornase alpha trial and
discontinued therapy; Group 3—patients who had a negative dornase alpha trial; data presented as mean (S.D.).
F value for ANOVA comparing groups 1, 2 and 3.a
Significantly different from group 1 (at P-0.05 level).*
respond (Table 1). Twelve patients (13%) surveyed had
not previously had a dornase alpha trial and a further 1
patient (1%) having severe lung disease (FVC-40%
predicted) had self-funded dornase alpha for 3 years.
Of patients completing a dornase alpha trial, 72%
fulfilled the criteria set for its ongoing funding of
therapy (group 1 and 2). Of these patients, 76% contin-
ued to collect some dornase alpha from the pharmacy
during 1999.
3.1. Adherence assessment by patients self-reporting and
pharmacy-dispensing records
Ten of 42 patients (24%) demonstrated good adher-
ence, 20 patients (48%) moderate adherence, and 12
(28%) poor adherence. Only three patients collected 12
months’ supply of dornase alpha in the period of the
study. The overall adherence for the group was 54%
(197 daysyyear). Over 80% of patients who continued
to use dornase alpha stated that they took treatment
more than 20 daysymonth (group 1). When compared
with pharmacy-dispensing records, only 24% of patients
collected sufficient dornase alpha to allow treatment for
more than 20 daysymonth.
Over 50% of patients reported dornase alpha to have
good to excellent effectiveness (visual analogue scores
w8–10x). There was no difference between reported
effectiveness ratings for patients with good, moderate or
poor adherence (data not shown).
3.2. Patients not receiving dornase alpha under Section
100 criteria
Twelve of 13 patients who had an initial favourable
response to dornase alpha and had discontinued treat-
ment (group 2), described little ongoing benefit, andy
or found nebulisation time-consuming. One patient
stated that it was too effective and reported being
uncomfortable because of copious thin secretions.
Only 1 of 22 patients who had an initial negative
dornase alpha trial (group 3) perceived symptomatic
benefit during the trial period. One other patient was
interested in considering a retrial at the time of the
survey. Two patients have had a subsequent successful
retrial.
Of the 12 patients who had not had a dornase alpha
trial, several reported that they felt too well at present,
but would consider therapy if their disease progressed.
Several of patients were interested in having a dornase
alpha trial at the time of the survey.
3.3. Health care professionals assessment of adherence
The adult CF physician and CF nurse specialist
correctly assessed adherence in 50–70% of cases.
Adherence was over-estimated (30%) more often than
under-estimated (13%).
3.4. Changes in pulmonary function following dornase
alpha trial
Spirometry was greater in patients who had a negative
trial of dornase alpha at the time of the trial (Table 1).
There was a negative correlation between the initial
response to dornase alpha (groups 1 and 2) and baseline
FEV (rsy0.44, Ps0.001). The change in FEV 31 1
years after the trial was not significantly different
between groups (Fs1.28, Ps0.29) (Table 2). The
initial response to dornase alpha was not related to the
change in FEV over 3 years (rs0.20, Ps0.16). The1
change in FEV at 3 years was not influenced by1
adherence to dornase alpha as determined by pharmacy
records (Fs2.49, Ps0.10).
4. Discussion
Dornase alpha improves pulmonary function and may
decrease the frequency of pulmonary exacerbations in
patients with moderate lung disease and CF w3–6x.
Criteria for prescription of dornase alpha vary between
and within health systems. Dornase alpha is expensive
with a current cost of US$6600 per patient per annum
and in Australian clinical practice an effective trial of
dornase alpha is required for its ongoing funding. The
long-term effectiveness, utilisation and adherence in
patients with CF have not been extensively studied.
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Table 2
Change in lung function immediately after and 3 years after a dornase alpha trial
Group 1 (ns42) Group 2 (ns13) Group 3 (ns22)
FEV (at baseline) (l)1 2.0 (0.7) 1.9 (0.6) 2.4 (0.9)*
FEV (at baseline) (% predicted)1 53.3 (15.5) 54.1 (20.4) 66.5 (20.2)*
FEV response to trial (%)1 21.2 (17.2) 17.6 (10.0) 0.1 (5.7)**
FEV (at 3 years) (l)1 2.1 (0.8) 2.1 (1.0) 2.3 (1.0)
FEV (at 3 years) (% predicted)1 54.6 (18.3) 56.1 (25.9) 61.6 (23.0)
Change in FEV1 (at 3 years) (l) 0.1 (0.5) 0.2 (0.8) y0.1 (0.4)
Group 1—patients who had a positive dornase alpha trial and continued therapy; Group 2—patients who had a positive dornase alpha trial and
discontinued therapy; Group 3—patients who had a negative dornase alpha trial; data presented as mean (S.D.).
Group 3 significantly different from group 1 and 2 (at P-0.05 level).*
Group 3 significantly different from group 1 and 2 (at P-0.0001 level).**
Over 70% of patients in our clinic fulfilled criteria for
ongoing dornase alpha therapy as determined by the
Australian government. However, after 3 years more
than 1 in 5 of these patients had ceased therapy, and
this was either due to a perceived lack of efficacy andy
or the time taken to undergo treatment or too much
efficacy (1 patient).
Of patients who continued to collect dornase alpha,
adherence, as determined by drug collection, varied
markedly. Patients collected 54% of dornase alpha pre-
scribed in 1999. Only 24% of patients collected 8 or
more months of dornase alpha, despite 80% of patients
reporting utilisation of 8 or more months. The current
study demonstrated marked differences between reported
adherence rates and pharmacy-dispensing records. This
may be due in part to patients wishing ‘to do the right
thing’, and fear the consequences of admitting poor
adherence. The overall adherence rates reported here are
similar to that in another Australian adult CF clinic w12x.
It is notable that the patients’ rating of efficacy of
dornase alpha was not related to drug collection.
Reduced adherence with treatment regimens is common
in patients with chronic disease. A meta-analysis exam-
ined adherence in patients receiving long-term medica-
tion and reported an adherence rate of 51% w13x. In
adolescents with chronic disease, only 11% of patients
demonstrated good adherence with all components of
treatment w14x. Similar adherence rates have been report-
ed in adults with CF. Conway et al. reported that over
50% of adults with CF self-reported taking over 80% of
therapy w10x. Another British study reported wide vari-
ations of adherence which were more dependent on the
specific nature of the therapy than on disease severity
or socio-economic status w11x. More than 80% of
patients with CF were adherent with pancreatic enzymes
and exercise, but less than one half of the patients were
adherent with vitamin therapy. In a recent review, Kettler
et al. reinforce that adherence will be less consistent
when treatments are complex and time consuming w15x.
Direct measurement of adherence in a clinical setting
may be difficult, particularly when treatment involves
multiple therapies, which can be accessed via a variety
of sources. As patients have limited access to dornase
alpha only through hospital pharmacies, comparison
between self-reported adherence and drug collection
from the dispensary is feasible. This allows an indirect
assessment of adherence but collection of drugs from
the pharmacy does not equate to drug administration,
which is a limitation of our study. Self-reporting has
been shown to over-estimate adherence when compared
with more direct measurements of adherence w15x. How-
ever, Sclar, who demonstrated that dispensing records
provide an indirect but objective measure of adherence
w16x, supports the approach reported here.
Clinical judgement of health professionals when
assessing patient adherence is poor. The ability of family
doctors to predict adherence of patients with digoxin
therapy was no better than chance, even for patients
who were well known in the practice w17x. In CF,
Conway et al. reported that health care providers were
poor judges of adherence w10x. However, physiotherap-
ists and physicians in another large adult CF clinic were
more often able to accurately determine adherence for
physiotherapy and exercise w11x. Self-reported and phy-
sician reported adherence indicate that adherence to
short-term interventions are higher than for longer-term
interventions w15x. In the current study, staff who knew
the patients well were not able to reliably predict drug
collection and notably health professionals tended to
over-estimate rather than under-estimate adherence.
Using the Australian criteria for funding of dornase
alpha, patients who had a negative trial (-10%
improvement in FEV ) had better lung function than1
those who had a positive trial. As a group, patients who
had an positive dornase alpha trial and continued on
therapy had a similar lung function after 3 years’ therapy.
These results could indicate that the short term improve-
ment in spirometry does not result in better preservation
of lung function in the medium term. However, our
study involves relatively small numbers of patients and
the lack of detection of group differences may relate to
the size of the population studied (type II error). A
retrospective study by Milla of a larger patient group
reported that the introduction of dornase alpha was not
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followed by a positive trend in pulmonary function or
nutritional parameters after 2 years, compared with the
2 years prior to dornase alpha treatment w9x. Milla’s
findings appeared to contrast with favourable responses
to the drug demonstrated in short-term randomised
controlled trials (up to 6 months), the published expe-
rience in the open labelled extension trial (18 months)
and a retrospective review of the experience in a
paediatric unit w3–8x. A recent Cochrane review of
dornase alpha for CF concluded that while therapy is
associated with an improvement in lung function after
6 months treatment, it is not possible to assess whether
this effect is sustained in the long-term w18x.
There is limited information relating adherence to
different treatments and their health outcomes in CF
w15x. The change in spirometry over 3 years did not
appear to be influenced by adherence to the therapy.
The lack of difference in change in lung function may
also be effected by sub-optimal adherence to dornase
alpha diluting any positive effect of therapy. We have
demonstrated that a minority of patients have moderate
to good adherence 3 years after commencing therapy.
Whether reduced adherence or limited long-term effi-
cacy is responsible for the lack of group differences is
uncertain. The current study and that by Milla support
the need for further study of the long-term effects of
dornase alpha w9x.
We report results that demonstrate sub-optimal adher-
ence to dornase alpha and highlights that clinicians
managing these patients should consider these findings
when reviewing therapy and writing repeat prescriptions.
The reasons for poor adherence are likely to include
perception of poor effectiveness, complexity and the
commitment of overall therapy, and inadequate educa-
tion of the purpose of the treatment. Further study of
the determinants of sub-optimal adherence and patient
beliefs about treatments in CF is needed. Interventions
to increase adherence have not been comprehensively
studied in patients with CF. Study of strategies to
improve adherence and their effective implementation
remains an important challenge in the management of
young people with CF. This has been emphasised in
another recent Cochrane review of ‘Interventions for
helping patients to follow prescriptions for medications’
in the general population which concluded that innova-
tive approaches to assist patients to follow medication
prescriptions are required w19x.
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